Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
10.27
-0.06 (-0.58%)
At close: Mar 6, 2026, 4:00 PM EST
10.27
0.00 (0.00%)
After-hours: Mar 6, 2026, 4:10 PM EST
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Ocular Therapeutix stock have an average target of 22.9, with a low estimate of 17 and a high estimate of 31. The average target predicts an increase of 122.98% from the current stock price of 10.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ocular Therapeutix stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Clear Street | Clear Street | Strong Buy Maintains $21 → $28 | Strong Buy | Maintains | $21 → $28 | +172.64% | Mar 3, 2026 |
| Needham | Needham | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | +75.27% | Feb 20, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +104.48% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +104.48% | Dec 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +94.74% | Dec 8, 2025 |
Financial Forecast
Revenue This Year
56.81M
from 51.95M
Increased by 9.35%
Revenue Next Year
109.57M
from 56.81M
Increased by 92.88%
EPS This Year
-1.36
from -1.42
EPS Next Year
-1.24
from -1.36
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 66.8M | 290.9M | |||
| Avg | 56.8M | 109.6M | |||
| Low | 51.0M | 51.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.5% | 412.0% | |||
| Avg | 9.3% | 92.9% | |||
| Low | -1.9% | -8.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.13 | -0.58 | |||
| Avg | -1.36 | -1.24 | |||
| Low | -1.68 | -1.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.